Sivalingam Kalai Selvi, Paramasivan Poornima, Weng Ching Feng, Viswanadha Vijaya Padma
Translational Research Laboratory, Department of Biotechnology, School of Biotechnology and Genetic Engineering, Bharathiar University, Coimbatore, Tamil Nadu, India.
Laboratory of Molecular Physiology, Department of Life Sciences, Institute of Biotechnology, National Dong Hwa University, Hualien 974, Taiwan.
J Cell Biochem. 2017 Sep;118(9):2865-2876. doi: 10.1002/jcb.25937. Epub 2017 Apr 27.
Cisplatin is one of the most potent chemotherapeutic agents for the treatment of many types of solid tumors but its efficacy is often limited by the development of resistance and dose limiting toxicity. Neferine is an alkaloid isolated from seed embryo of Nelumbo nucifera, it has recently been shown to have anticancer effects in various human cancer cell lines. The present investigation is designed to study the chemosensitizing ability of neferine with cisplatin in A549 cells. Neferine potentiates the cisplatin induced apoptosis through the exploration of characteristic apoptotic morphological changes, induced sub-G1 cell cycle arrest, ROS hypergeneration, significant loss of cellular antioxidant enzymes, as well as loss of mitochondrial membrane potential (ΔΨM). Furthermore our results revealed that neferine combined with cisplatin down regulate the expression of Bcl-2 and up regulate the expression of Bax, Bad, Bak, release of cytochrome c, p53 levels, then activated cleavage forms of caspase-9, caspase-3, and PARP. Moreover neferine and cisplatin combination significantly down regulated the protein levels of FAK and VEGF. In addition, we observed the activity of MMP-2 and MMP-9. Thus this study provides molecular evidence for the ROS mediated apoptosis of the combinatorial regimen of cisplatin and neferine in lung cancer cells. Thus these results suggest that using neferine with cisplatin combinatorial regimen could be potentiating the effect of cisplatin and neferine reduces the cisplatin dose requirement in cancer chemotherapy. J. Cell. Biochem. 118: 2865-2876, 2017. © 2017 Wiley Periodicals, Inc.
顺铂是治疗多种实体瘤最有效的化疗药物之一,但其疗效常常受到耐药性的产生和剂量限制性毒性的限制。甲基莲心碱是从莲种子胚中分离出的一种生物碱,最近研究表明它在多种人类癌细胞系中具有抗癌作用。本研究旨在探讨甲基莲心碱对A549细胞中顺铂化疗的增敏作用。甲基莲心碱通过引发典型的凋亡形态学变化、诱导亚G1期细胞周期阻滞、活性氧大量生成、细胞抗氧化酶显著丧失以及线粒体膜电位(ΔΨM)丧失,增强顺铂诱导的细胞凋亡。此外,我们的结果显示,甲基莲心碱与顺铂联合使用可下调Bcl-2的表达,上调Bax、Bad、Bak的表达,促使细胞色素c释放、p53水平升高,进而激活半胱天冬酶-9、半胱天冬酶-3和聚(ADP-核糖)聚合酶(PARP)的裂解形式。此外,甲基莲心碱与顺铂联合使用可显著下调黏着斑激酶(FAK)和血管内皮生长因子(VEGF)的蛋白水平。另外,我们还观察了基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)的活性。因此,本研究为甲基莲心碱与顺铂联合用药通过活性氧介导肺癌细胞凋亡提供了分子证据。这些结果表明,甲基莲心碱与顺铂联合用药方案可增强顺铂的疗效,且甲基莲心碱可降低癌症化疗中顺铂的剂量需求。《细胞生物化学杂志》2017年第118卷:2865 - 2876页。© 2017威利期刊出版公司